ijms-logo

Journal Browser

Journal Browser

Melanoma: From Molecular Pathology to Therapeutic Approaches, 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 1178

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand
Interests: genomics; epigenomics; melanomas; human cancer; PAX genes; transcriptomic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

While melanoma is one of the most aggressive and devastating cancer types, major advances in both melanoma targeted therapy as well as immunotherapy over the past two decades have revolutionised melanoma treatment. These advances have been driven by technical innovation, which is aimed at targeting molecular pathological biomarkers, facilitating the death of melanoma cells.

However, despite these therapeutic advances, a significant proportion of melanoma patients do not benefit from these treatments, which is due to either innate or acquired treatment resistance in the melanomas.

In this Special Issue, we welcome authors to submit original research and review articles that contribute to a better understanding of molecular pathological biomarkers and mechanisms leading to treatment resistance in melanoma. Topics of interest include, but are not limited to, the following:

  • Intrinsic therapeutic resistance mechanisms, immune pathways, or tumor microenvironmental factors affecting cutaneous, mucosal, uveal, or other melanoma types.
  • Novel small molecules or environmental factors affecting treatment resistance or therapeutic response in melanoma.
  • Individual “omics” or “integrated omics” studies of molecular (nucleotide variant, gene expression, or epigenetic) mechanisms involved in melanoma treatment response.
  • Relationships between gene expression and epigenetic mechanisms of therapeutic response in melanoma.
  • New therapeutic strategies (including combination therapeutic approaches) targeting melanoma tissues.

Prof. Dr. Michael Eccles
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • pathology
  • therapeutic approaches

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

31 pages, 11557 KB  
Article
Regulatory Mechanisms of SPARC Overexpression in Melanoma Progression
by Antònia Vinyals, Josep R. Ferreres, Rafael Campos-Martín, Olga J. C. Torres, Jessica Mainez, Joan A. Puig-Butillé, Joaquim Marcoval, Susana Puig, Isabel Fabregat and Àngels Fabra
Int. J. Mol. Sci. 2025, 26(17), 8743; https://doi.org/10.3390/ijms26178743 - 8 Sep 2025
Viewed by 851
Abstract
The expression of the Secreted Protein, Acidic and Rich in Cysteine (SPARC) gene in human melanoma increases during progression and is associated with epithelial-to-mesenchymal transition (EMT), which is a major determinant of metastasis in melanoma patients. However, the underlying molecular mechanisms [...] Read more.
The expression of the Secreted Protein, Acidic and Rich in Cysteine (SPARC) gene in human melanoma increases during progression and is associated with epithelial-to-mesenchymal transition (EMT), which is a major determinant of metastasis in melanoma patients. However, the underlying molecular mechanisms that control SPARC expression in this context remain elusive. Herein, we identified Paired-related homeobox 1 (PRRX1), an EMT transcription factor, as a transcriptional activator of SPARC by direct binding to the promoter, thereby increasing its activity. Moreover, we found a strong positive correlation between SPARC and PRRX1 expression levels in clinical samples and cell lines. Furthermore, the switch from the proliferative/melanocytic phenotype toward the invasive/mesenchymal-like phenotype favors the expression of TCF7L2, a β-catenin cofactor, which, together with Sp1, binds to the proximal SPARC promoter, thereby bolstering protein expression. We also show that SPARC is a target of the miR-29 family, whose members are expressed in clinical melanoma samples and cell lines. Indeed, we found that miR-29b1~a expression is inversely correlated with SPARC levels, and it is significantly reduced in samples with a mesenchymal-like phenotype. Taken together, SPARC expression in melanoma cells relies on transcriptional activation by PRRX1/TCF7L2-Sp1 and is modulated through miR-29b1~a, which provides fine-tuning regulation over the switch between phenotypic states. Full article
Show Figures

Graphical abstract

Back to TopTop